Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOTI N RAMGOPAL

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1457329450
CMS profile
111584
Location
FORT PIERCE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$199,839.10

238 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $121,888.20 124
Gilead Sciences, Inc. $61,597.63 73
Merck Sharp & Dohme LLC $6,523.05 20
Shionogi Inc $5,043.45 2
ABBVIE INC. $4,451.52 5
Insmed, Inc. $255.07 10
Theratechnologies Inc. $54.78 3
Melinta Therapeutics, LLC $25.40 1

Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOTI N RAMGOPAL

NPI 1457329450 · CMS profile ID 111584

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

FORT PIERCE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457329450?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOTI N RAMGOPAL, NPI 1457329450, CMS profile ID 111584. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457329450?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MOTI N RAMGOPAL, NPI 1457329450, CMS profile ID 111584. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457329450?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MOTI N RAMGOPAL, NPI 1457329450, CMS profile ID 111584, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1457329450?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

238 matching records · $199,839.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 238 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 238.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $34.0707/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141805659 CMS
ViiV Healthcare Company $80.3207/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112804675 CMS
Gilead Sciences, Inc. $122.8907/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133817829 CMS
Gilead Sciences, Inc. $472.2607/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133868238 CMS
Gilead Sciences, Inc. $46.5107/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133817335 CMS
ABBVIE INC. $22.9307/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105363836 CMS
Gilead Sciences, Inc. $16.3207/22/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1156084569 CMS
Insmed, Inc. $4.4907/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089561214 CMS
ABBVIE INC. $33.7907/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105363832 CMS
Gilead Sciences, Inc. $1,780.0007/18/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133599771 CMS
ViiV Healthcare Company $5,200.0007/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112713188 CMS
ViiV Healthcare Company $29.0007/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112817381 CMS
ViiV Healthcare Company $181.0707/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112759500 CMS
ViiV Healthcare Company $384.0707/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112813675 CMS
Merck Sharp & Dohme LLC $24.1907/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141965949 CMS
Gilead Sciences, Inc. $20.9506/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133817827 CMS
Insmed, Inc. $20.1006/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089564844 CMS
Gilead Sciences, Inc. $43.6006/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133817821 CMS
Gilead Sciences, Inc. $45.7806/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133817823 CMS
Gilead Sciences, Inc. $148.3806/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133817825 CMS
Gilead Sciences, Inc. $60.9406/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133868236 CMS
ViiV Healthcare Company $20.1606/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112723126 CMS
ViiV Healthcare Company $23.2206/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112735061 CMS
ViiV Healthcare Company $1,300.0006/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112797728 CMS
ViiV Healthcare Company $6.5606/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112766172 CMS
ViiV Healthcare Company $59.1906/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112817711 CMS
Gilead Sciences, Inc. $76.4606/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133817819 CMS
Merck Sharp & Dohme LLC $33.8306/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141948578 CMS
ViiV Healthcare Company $2.1606/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112811259 CMS
ViiV Healthcare Company $3,900.0006/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112828051 CMS
Gilead Sciences, Inc. $18.5005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133817817 CMS
ViiV Healthcare Company $28.5605/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112727461 CMS
ViiV Healthcare Company $23.3505/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112733601 CMS
ViiV Healthcare Company $3,900.0005/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1155883714 CMS
Gilead Sciences, Inc. $1,950.0005/15/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133599769 CMS
ViiV Healthcare Company $8,450.0005/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112726656 CMS
Merck Sharp & Dohme LLC $21.4405/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141901676 CMS
ViiV Healthcare Company $3,900.0005/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112772476 CMS
ViiV Healthcare Company $3,900.0005/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112776728 CMS
ViiV Healthcare Company $120.6505/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112803627 CMS
Gilead Sciences, Inc. $2,950.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133607598 CMS
ViiV Healthcare Company $650.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112723710 CMS
ViiV Healthcare Company $83.7505/08/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155883606 CMS
Insmed, Inc. $19.2605/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089577300 CMS
ViiV Healthcare Company $24.9205/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112746605 CMS
ViiV Healthcare Company $106.5305/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112710172 CMS
Theratechnologies Inc. $13.4204/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092907317 CMS
ViiV Healthcare Company $170.8504/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112745595 CMS
ViiV Healthcare Company $710.6004/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112739471 CMS
ViiV Healthcare Company $23.8804/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112788626 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $259,646.72 386
PY2020 $113,830.70 147
PY2021 $71,522.13 114
PY2022 $173,290.00 257
PY2023 $169,755.89 239
PY2024 $199,839.10 238
PY2025 $148,155.48 223

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $876,162.78 88
PY2024 Principal investigator $913,331.48 132
PY2023 Recipient $4,544.19 28
PY2023 Principal investigator $1,348,202.63 146
PY2022 Recipient $1,802.53 4
PY2022 Principal investigator $1,483,703.75 229
PY2021 Principal investigator $4,459,284.19 247
PY2020 Recipient $1,205.69 15
PY2020 Principal investigator $2,059,469.36 292
PY2019 Principal investigator $1,196,574.01 259

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $4.16 12/31/2025 Non-covered Recipient Entity
Midway Immunology and Research Center
A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. No dispute reported 06/30/2026 1232928664
Principal investigator 1 Merck Sharp & Dohme LLC $44,107.63 12/31/2025 Non-covered Recipient Entity
Midway Immunology and Research Center
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine,Islatravir DOR,ISL 100 mg,0.25 mg Once-Daily in HIV-1 Infected Treatment-Na ve Participants No dispute reported 06/30/2026 1232933722
Principal investigator 1 Merck Sharp & Dohme LLC $2,640.49 12/31/2025 Non-covered Recipient Entity
Midway Immunology and Research Center
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV No dispute reported 06/30/2026 1232933878
Principal investigator 1 Merck Sharp & Dohme LLC $288,355.71 12/31/2025 Non-covered Recipient Entity
Midway Immunology and Research Center
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL 100 mg,0.25 mg Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alaf No dispute reported 06/30/2026 1232938168
Principal investigator 1 Gilead Sciences, Inc. $761.00 12/16/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219562
Principal investigator 1 ViiV Healthcare Company $25,640.90 11/19/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315563
Principal investigator 1 Gilead Sciences, Inc. $2,283.00 11/18/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219555
Principal investigator 1 ViiV Healthcare Company $8,850.00 11/13/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
AN EXPLORATORY PHASE 1B, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO No dispute reported 06/30/2026 1190315225
Principal investigator 1 ViiV Healthcare Company $1,300.00 11/13/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190315769
Principal investigator 1 ViiV Healthcare Company $500.00 11/13/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190318809
Principal investigator 1 ABBVIE INC. $5,143.80 11/04/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202520403
Principal investigator 1 ViiV Healthcare Company $3,433.40 11/04/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
AN EXPLORATORY PHASE 1B, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO No dispute reported 06/30/2026 1190315217
Principal investigator 1 ViiV Healthcare Company $1,413.10 11/04/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315767
Principal investigator 1 ViiV Healthcare Company $5,576.25 11/04/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
AN EXPLORATORY PHASE 1B, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO No dispute reported 06/30/2026 1190318491
Principal investigator 1 ViiV Healthcare Company $21,972.60 10/31/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315583
Principal investigator 1 ViiV Healthcare Company $2,847.97 10/23/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
AN EXPLORATORY PHASE 1B, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO No dispute reported 06/30/2026 1190318495
Principal investigator 1 Gilead Sciences, Inc. $2,462.00 10/21/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219543
Principal investigator 1 GlaxoSmithKline, LLC. $400.00 10/20/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192114157
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 10/20/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192120636
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 10/20/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192174077
Principal investigator 1 GlaxoSmithKline, LLC. $39.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192114162
Principal investigator 1 GlaxoSmithKline, LLC. $130.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192120310
Principal investigator 1 GlaxoSmithKline, LLC. $35.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192120316
Principal investigator 1 GlaxoSmithKline, LLC. $39.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192120319
Principal investigator 1 GlaxoSmithKline, LLC. $35.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192120326
Principal investigator 1 GlaxoSmithKline, LLC. $70.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192120627
Principal investigator 1 GlaxoSmithKline, LLC. $39.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192120641
Principal investigator 1 GlaxoSmithKline, LLC. $39.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192120648
Principal investigator 1 GlaxoSmithKline, LLC. $35.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192175008
Principal investigator 1 GlaxoSmithKline, LLC. $78.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192175011
Principal investigator 1 GlaxoSmithKline, LLC. $361.40 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192175015
Principal investigator 1 GlaxoSmithKline, LLC. $70.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192175024
Principal investigator 1 GlaxoSmithKline, LLC. $130.00 10/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192177864
Principal investigator 1 ViiV Healthcare Company $33,291.41 09/18/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318489
Principal investigator 1 Gilead Sciences, Inc. $3,402.00 09/16/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219536
Principal investigator 1 ABBVIE INC. $1,310.40 09/03/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202507825
Principal investigator 1 ViiV Healthcare Company $847.50 09/02/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190318811
Principal investigator 1 Gilead Sciences, Inc. $10,206.00 08/19/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219515
Principal investigator 1 Gilead Sciences, Inc. $1,820.00 08/19/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219525
Principal investigator 1 ViiV Healthcare Company $58,066.36 08/15/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315579
Principal investigator 1 ViiV Healthcare Company $750.00 08/07/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190318759
Principal investigator 1 ViiV Healthcare Company $5,079.10 08/07/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318765
Principal investigator 1 ViiV Healthcare Company $322.50 08/07/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318799
Principal investigator 1 Gilead Sciences, Inc. $5,500.00 08/05/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219507
Principal investigator 1 ViiV Healthcare Company $30,160.14 07/24/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318497
Principal investigator 1 Gilead Sciences, Inc. $6,479.00 07/22/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219497
Principal investigator 1 Gilead Sciences, Inc. $800.00 07/08/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219467
Principal investigator 1 Gilead Sciences, Inc. $1,170.00 07/08/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219477
Principal investigator 1 Gilead Sciences, Inc. $1,350.00 07/08/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219487
Principal investigator 1 ViiV Healthcare Company $5,257.98 07/08/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318757
Principal investigator 1 ViiV Healthcare Company $1,300.00 06/25/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND (SPONSOR-UNBLINDED), PLACEBO-CONTROLLED, AD No dispute reported 06/30/2026 1190315227
Principal investigator 1 ViiV Healthcare Company $500.00 06/25/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND (SPONSOR-UNBLINDED), PLACEBO-CONTROLLED, AD No dispute reported 06/30/2026 1190318493
Principal investigator 1 Gilead Sciences, Inc. $4,274.00 06/17/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219459
Principal investigator 1 GlaxoSmithKline, LLC. $1,103.02 06/12/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192177860
Principal investigator 1 ViiV Healthcare Company $995.80 06/12/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318761
Principal investigator 1 ViiV Healthcare Company $29,089.55 06/11/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315561
Principal investigator 1 Gilead Sciences, Inc. $3,700.00 06/03/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV No dispute reported 06/30/2026 1229202621
Principal investigator 1 ViiV Healthcare Company $40,536.87 05/26/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318535
Principal investigator 1 Gilead Sciences, Inc. $6,880.00 05/20/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219446
Principal investigator 1 ViiV Healthcare Company $37,507.47 04/28/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315581
Principal investigator 1 Gilead Sciences, Inc. $5,504.00 04/22/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219434
Principal investigator 1 ViiV Healthcare Company $1,095.12 04/10/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318807
Principal investigator 1 ViiV Healthcare Company $1,980.81 04/08/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190318805
Principal investigator 1 ViiV Healthcare Company $750.00 04/02/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315565
Principal investigator 1 ViiV Healthcare Company $6,500.00 04/02/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318531
Principal investigator 1 ViiV Healthcare Company $1,600.00 04/02/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318533
Principal investigator 1 ViiV Healthcare Company $59,487.27 03/25/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 1190315223
Principal investigator 1 ViiV Healthcare Company $11,657.30 03/21/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315219
Principal investigator 1 ViiV Healthcare Company $7,660.42 03/21/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315221
Principal investigator 1 Gilead Sciences, Inc. $5,103.00 03/18/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219418
Principal investigator 1 ViiV Healthcare Company $1,914.90 03/11/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318763
Principal investigator 1 ViiV Healthcare Company $647.50 03/11/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318801
Principal investigator 1 ViiV Healthcare Company $1,500.00 03/11/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318803
Principal investigator 1 ABBVIE INC. $1,446.90 03/07/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202459392
Principal investigator 1 GlaxoSmithKline, LLC. $1,030.48 03/06/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192174087
Principal investigator 1 Gilead Sciences, Inc. $18,908.00 02/19/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219404
Principal investigator 1 ABBVIE INC. $560.00 02/12/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202450665
Principal investigator 1 ABBVIE INC. $760.00 02/12/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202450669
Principal investigator 1 ABBVIE INC. $5,105.12 02/06/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202447961
Principal investigator 1 Gilead Sciences, Inc. $1,050.00 01/28/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV No dispute reported 06/30/2026 1229202613
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 01/28/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192174084
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 01/28/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192175019
Principal investigator 1 ViiV Healthcare Company $846.57 01/28/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH CENTER
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 1190315585
Principal investigator 1 ViiV Healthcare Company $6,968.52 01/28/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190318755
Principal investigator 1 ViiV Healthcare Company $3,876.21 01/28/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND RESEARCH
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318813
Principal investigator 1 Gilead Sciences, Inc. $1,122.00 01/22/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV No dispute reported 06/30/2026 1229202606
Principal investigator 1 Gilead Sciences, Inc. $12,183.00 01/22/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY & RESEARCH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219391
Principal investigator 1 ABBVIE INC. $2,764.15 01/02/2025 Non-covered Recipient Entity
MIDWAY IMMUNOLOGY AND
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202434461